Flavonoids Show Therapeutic Potential in NAFLD Management: Study
A new meta-analysis suggests that flavonoid supplementation offers promising benefits for people with non-alcoholic fatty liver disease (NAFLD). Researchers reviewed 25 randomized controlled trials involving more than 1,600 participants to evaluate how different types of flavonoids—such as quercetin, anthocyanins, genistein, silymarin, and naringenin—affect liver health, blood lipids, and insulin sensitivity. The findings showed significant reductions in liver enzymes (ALT, AST, ALP), total cholesterol, triglycerides, fasting blood sugar, insulin levels, and body mass index. Participants also showed improved insulin sensitivity, suggesting that flavonoids may help manage early metabolic dysfunction linked to fatty liver.
Despite these improvements, the study found limited effects on inflammation and liver fibrosis, which are key indicators of disease progression. While flavonoids lowered markers of liver stress, they did not significantly improve γ-glutamyl transferase (GGT), LDL or HDL cholesterol, or fibrosis scores. Researchers explained that this might be due to differences in study design, dosage, and the specific types of flavonoids used. They also noted that liver fibrosis develops slowly, and many trials were too short to capture meaningful structural changes. For that reason, longer studies using advanced imaging or biopsy assessments are needed to determine whether flavonoids can slow or reverse fibrosis.
In essence, flavonoids appear to be a helpful add-on rather than a replacement for standard NAFLD management. Their strongest benefits seem to be in improving liver enzyme levels, metabolic function, and lipid balance. Researchers emphasize the need for large-scale, long-term clinical trials to confirm the safety, ideal dosage, and potential synergistic effects when used alongside other therapies. For now, incorporating flavonoid-rich foods such as berries, citrus fruits, soy, and green tea could support liver and metabolic health while further research continues.
